Kimberly Pennix

Kimberly Pennix supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing strategic procurement actions that advance regulatory science and sustain critical research infrastructure. She manages a diverse portfolio of acquisitions focused on scientific and technical services essential to the FDA’s mission of ensuring drug safety, efficacy, and medical device security. Her work centers on securing specialized research capabilities, analytical instrumentation support, and high-compliance laboratory services that directly enable the agency’s scientific review and inspection functions. Pennix routinely handles complex, performance-based contracts requiring deep technical expertise and strict adherence to federal acquisition regulations. She maintains consistent working relationships with key contractors including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for niche providers with proven capabilities in biopharmaceutical research, toxicology, and clinical trial support. These partnerships are characterized by long-term, mission-critical engagements that demand high levels of regulatory alignment and scientific rigor. Her contracting approach emphasizes vendor reliability, technical specificity, and compliance with Good Laboratory Practices and FDA quality standards. Pennix’s procurement patterns reflect a strong emphasis on open competition, with 80% of awards issued without set-asides. However, she actively supports small business participation, with 20% of contracts reserved for Total Small Business Set-Asides under FAR 19.5, demonstrating a balanced commitment to both operational efficiency and socioeconomic goals. Her contracting decisions prioritize capability over size, ensuring that qualified small businesses with specialized scientific expertise are competitively considered. Her primary procurement focus lies in NAICS 541714 (Biotechnology R&D), 541380 (Testing Laboratories), and 541690 (Scientific Consulting Services), underscoring her deep engagement with preclinical research, analytical testing, and regulatory science consulting. She consistently procures services involving bioanalytical validation, toxicological assessment, and clinical trial support—domains requiring precise technical qualifications and adherence to federal compliance frameworks.